SAB Biotherapeutics, Inc.
SABSWHeld by 5 specialist biotech funds
High Convergence5 funds opened new positions. Next phase2 readout (High Dose SAB-142): Nov 2027.
SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.